Does low peritoneal glucose load protect from the development of left ventricular hypertrophy in peritoneal dialysis

Kamal Hassan1,2,3, Fadi Hassan4, Dunia Hassan5

  • 1Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel. drkamalh@hotmail.com.

Insights

Low peritoneal glucose load may protect peritoneal dialysis patients from left ventricular hypertrophy. Patients with high glucose load experienced greater increases in left ventricular mass index.

Area of Science:

  • Nephrology
  • Cardiology
  • Biomedical Engineering

Background:

  • Left ventricular hypertrophy (LVH) is a significant predictor of cardiovascular events and a leading cause of mortality in peritoneal dialysis (PD) patients.
  • Understanding factors influencing LVH development is crucial for improving outcomes in PD patients.

Purpose of the Study:

  • To retrospectively investigate the impact of a low peritoneal glucose load on left ventricular mass (LVM) in patients undergoing PD.
  • To compare the progression of LVM in PD patients with high versus low peritoneal glucose loads.

Main Methods:

  • Retrospective analysis of 36 continuous ambulatory PD patients over 2 years.
  • Patients were divided into high peritoneal glucose load (HPGL) using glucose-based solutions and low peritoneal glucose load (LPGL) using alternative solutions when serum albumin decreased.
  • Data collected included medical history, physical findings, echocardiography, laboratory results, and hydration status at baseline and 24 months.

Main Results:

  • Mean left ventricular mass index (LVMI) increased in both groups, but the increment was significantly higher in the HPGL group.
  • At 24 months, the HPGL group showed higher peritoneal glucose load index (PGLI), fluid overload, mean arterial pressure (MAP), HbA1c, and hsCRP.
  • The LPGL group demonstrated higher 24-hour ultrafiltration, weekly Kt/V, serum albumin, and residual renal function (RRF).

Conclusions:

  • Low peritoneal glucose load appears to be associated with a protective effect against the development of LVH in PD patients.
  • Minimizing peritoneal glucose exposure may be a strategy to mitigate cardiac remodeling in PD patients.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
697
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
634
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
557
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
751
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
1.0K